Targeting cannabinoid receptor 1 for multiple sclerosis: molecular docking and dynamic insights of berberine and curcumin as potential therapeutic agents
American Journal of Clinical and Experimental Immunology · 2026 · 15 (3) · 193-202
DOI: 10.62347/bnnl4902 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical and Experimental Immunology, 2026. Verfasst von Jehan Alrahimi. Beteiligte Einrichtung: Department of Biological Sciences, Faculty of Science, King Abdulaziz University Jeddah 21589, Saudi Arabia. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biological Sciences, Faculty of Science, King Abdulaziz University Jeddah 21589, Saudi Arabia.
Zitieren
APA
Alrahimi, J. (2026). Targeting cannabinoid receptor 1 for multiple sclerosis: molecular docking and dynamic insights of berberine and curcumin as potential therapeutic agents. American Journal of Clinical and Experimental Immunology, 15(3), 193-202. https://doi.org/10.62347/bnnl4902
Vancouver
Alrahimi J. Targeting cannabinoid receptor 1 for multiple sclerosis: molecular docking and dynamic insights of berberine and curcumin as potential therapeutic agents. American Journal of Clinical and Experimental Immunology. 2026;15(3):193-202. doi:10.62347/bnnl4902
BibTeX
@article{Alrahimi2026,
author = {Alrahimi, Jehan},
title = {Targeting cannabinoid receptor 1 for multiple sclerosis: molecular docking and dynamic insights of berberine and curcumin as potential therapeutic agents},
journal = {American Journal of Clinical and Experimental Immunology},
year = {2026},
volume = {15},
number = {3},
pages = {193--202},
doi = {10.62347/bnnl4902}
}
EUVIMED